Aim: Different eukaryotic expression vectors were selected in this research, and then we respectively cloned and constructed recombinant plasmids contained HBX gene or its different fusion forms with GFP. We are aimed to explore the influence of the HBX protein with different structure on its intracellular localization.
Methods: Flag-HBX gene was amplified from pcDNA3.0-HBX plasmid in our laboratory, cloned into pMD-18T vectors, sequenced.and then subcloned into different vectors. After right sequenced, respective recombinant plasmids of pFlag- HBX-IRES2-EGFP, pEGFP-C3-Flag-HBX and pFlag-HBX-EGFP-N3 were transiently transfected into hepatoma HepG-2 cells. The intra-cellular localizations and distributions of HBX protein were examined by indirect immunofluorescence.
Results: Three different Flag-HBX eukaryotic expression vectors were successfully constructed. After transfection of them into HepG2 cells respectively, indirect immunofluorescence demonstrated that HBX protein fused with GFP in different forms show distint intra-cellular distribution characteristics.
Conclusion: We have provided significant experimental evidences for research of the role of HBX protein in the development of hepatocellular carcinoma, and especially the references for explanation of the outcomes in vitro transfection experiments.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
New thiourea derivatives that target the episomal silencing SMC5 protein to inhibit HBx-dependent viral DNA replication and gene transcription.
Virusdisease
December 2024
Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, D-1, Vasant Kunj, New Delhi, 110 070 India.
Unlabelled: Antivirals such as nucleotide analogs (NAs) are potent inhibitors of hepatitis B virus (HBV) replication. However, NAs fail to diminish the signaling and mitogenic activities of the transactivator HBx protein. Earlier we have shown that thiourea derivative IR-415 (DSA-00) targeted HBx to down-regulate its target viral and host genes.
View Article and Find Full Text PDFHBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma.
Cancer Res
December 2024
University of California, San Francisco, San Francisco, CA, United States.
Hepatitis B virus (HBV) infections promote liver cancer initiation by inducing inflammation and cellular stress. Despite the primarily indirect effect on oncogenesis, HBV is associated with a recurrent genomic phenotype in HCC, suggesting that it impacts the biology of established HCC. Characterization of the interaction of HBV with host proteins and the mechanistic contributions of HBV to HCC initiation and maintenance could provide insights into HCC biology and uncover therapeutic vulnerabilities.
View Article and Find Full Text PDFMolecular Biological Mechanisms of Action of Chrysophanol in Hepatic Stellate Cells Activated by Hepatic B Virus X Based on Network Pharmacology.
Intervirology
December 2024
Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei, Taiwan.
Introduction: Chrysophanol (Cho) is a natural anthraquinone with biological effects such as inducing ferroptosis and anticancer activity. The hepatitis B virus X protein (HBx) is essential for HBV replication. We aimed to identify the key pathways in HBx-induced hepatic stellate cell (HSC) activation and to characterize the potential mechanisms of action of Cho against liver fibrosis.
View Article and Find Full Text PDFDesign of multi-epitope-based therapeutic vaccine candidates from HBc and HBx proteins of hepatitis B virus using reverse vaccinology and immunoinformatics approaches.
PLoS One
December 2024
School of Life Science and Technology, Institut Teknologi Bandung, Bandung, West Java, Indonesia.
Article Synopsis
- The primary challenge in chronic hepatitis B is the immune system's inability to eliminate the cccDNA associated with the virus.
- Researchers are working on a new therapeutic vaccine utilizing a multi-epitope approach based on HBc and HBx proteins to target various HBV genotypes.
- This vaccine candidate shows potential for strong immune responses, global effectiveness, and stability, indicating significant progress in combating chronic hepatitis B.
Mechanisms underlying the compromised clinical efficacy of interferon in clearing HBV.
Virol J
December 2024
Key Laboratory of Artificial Organs and Computational Medicine of Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, 8 Shuren St, Gongshu District, Hangzhou, 310015, Zhejiang Province, China.
Article Synopsis
- Hepatitis B virus (HBV) is a significant global health issue, with around 296 million chronic infections and 820,000 deaths annually linked to liver diseases caused by HBV by 2019.
- Current treatments for chronic HBV include nucleotide analogs (NAs) and interferons (IFNs), with IFN-α showing limited effectiveness due to HBV's ability to disrupt the IFN signaling pathway through various viral proteins.
- Research is focused on overcoming HBV resistance and improving IFN-α therapies, emphasizing the need for new treatment strategies to enhance patient outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!